ArticleThe journal of allergy and clinical immunology. Global2026
AAAAI physician survey: Current antihistamine use in the clinical setting.
Article in The journal of allergy and clinical immunology. Global, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: First-generation antihistamines (FGAs) are less selective for histamine receptor binding than second-generation antihistamines (SGA), with a resulting increased risk for untoward effects. Real-world use data by allergists and immunologists of FGAs versus SGAs is lacking in the literature. Objective: We assessed FGA versus SGA preference patterns and clinical uses by practicing allergists and immunologists in the United States. Methods: An anonymous survey was distributed by the AAAAI Practice, Diagnostics, and Therapeutics Committee to practicing member allergists and immunologists. Results: A total of 702 surveys were distributed with 85 respondents (12.1% response rate). Respondents practiced most commonly in private practice (55%, n = 45) and academic settings (34.57%, n = 28). Situation/location-specific preferences for using FGAs versus SGAs were reported: for in-office challenges, 66.67% (n = 50) preferred SGAs. Further, 64.47% (n = 49) preferred SGAs for home allergy action plans and 58.44% (n = 45) for school allergy action plans. Regarding complementary use in eczema, 44.74% (n = 34) preferred SGAs, 15.79% (n = 12) preferred FGAs, and 39.47% (n = 30) reported using both. There was a significant difference in preference between FGAs and SGAs based on years in practice, with those practicing for <10 years more likely to prefer SGAs. Conclusion: Variable use of FGAs versus SGAs exists among practicing allergists, demonstrating the need to improve education on the safety benefits of SGAs and highlight areas where they may be more useful than perceived.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.